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Modulating Avidity of h8F4-CAR by Regulation of Expression via Codon Modification
Rolando Antonio Vedia, B.S.
Advisory Professor: Jeffrey Molldrem, M.D.

Despite recent advances in the field of cancer immunotherapy and chimeric antigen
receptor (CAR) therapies for the treatment of acute myeloid leukemia (AML), there is a need for
more unique and innovative modalities to improve these therapies. Our group has extensively
studied and demonstrated the potential of targeting the leukemia-associated antigen PR1 in the
setting of AML. PR1 is an HLA-A2-restricted nonameric peptide derived from serine proteases
neutrophil elastase and proteinase 3, is overexpressed on myeloid leukemia cells, and expressed
at normal low levels in healthy hematopoietic cells. We have demonstrated efficacy in targeting
PR1/HLA-A2 via the novel development of a TCR-like monoclonal antibody named 8F4 and its
adaptation into a chimeric antigen receptor (CAR) named h8F4-CAR. As PR1/HLA-A2 is a selfantigen, its targeting renders increased susceptibility to on-target, off-tumor effects which is a
common adverse effect seen in other CAR therapies targeting self-antigens. In an attempt to find
an innovative manner to avoid this effect and optimize h8F4-CAR against the PR1/HLA-A2
complex, we investigated and conducted foundational studies using the genetic code and its
inherent codon bias. This was done by altering serine and arginine residues within the nonvariable regions of h8F4-CAR from their endogenous codons into the rare codon isoforms TCG
and CGT for serine and arginine, respectively. Synonymous codon modification of h8F4-CAR
represents a unique approach and strategy for modulating the affinity/avidity of CAR therapies
by introducing rarer, or less frequently used, codons that encode the same residue. Data from
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on-going studies in which rare synonymous codons were introduced show that expression of
h8F4-CAR can be altered. While MFI values across different codon-modified construct iterations
vary, immunoblotting results reveal presence of novel bands unique to codon-modified
constructs compared to unmodified wildtype h8F4-CAR and control cells. The introduction of
synonymous codon modifications, which takes advantage of inherent codon bias and frequency,
represents a unique strategy to mitigate on-target, off-tumor effects. This strategy can be used
to alter protein or biologic expression, providing a new approach to fine-tune and modulate CAR
avidity and potency leading to greater efficacy by increasing therapeutic indices and reducing
likelihood of adverse effects. These implications hold promise in not only in CARs but also in many
adoptive cellular therapy platforms in which the genetic code can be utilized to improve and
enhance therapies leading to favorable outcomes.
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Chapter 1: Introduction
Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a malignant cancer of the blood which manifests as
aberrant and unusual growth of healthy hematopoietic stem cells into leukemic progenitor cells
and blasts. Often, these aberrant leukemic blasts accumulate a plethora of mutations which have
been found to affect a variety of cell functions such as growth, differentiation, and proliferation.
In addition, the proliferation of these blasts occurs at the expense of normal, healthy myeloid
precursors and terminally differentiated cells like red blood cells, platelets, and granulocytes.
Commonly characterized features of AML include fatigue, anemia, neutropenia, and
thrombocytopenia, all of which are characteristic of bone marrow failure that occurs as AML
progresses and leukemic blasts accumulate in the marrow (1,2). The National Cancer Institute’s
SEER (Surveillance, Epidemiology & End Results) Program estimates that 0.5% of men and women
in the United States will develop AML over the course of their lives. The SEER program also
estimates that AML diagnoses will account for 1.1% of new cancer diagnoses and 1.8% of all
cancer deaths in the United States in 2020 alone. However, even more concerning is the 28.7%
5-year survival rate of the disease (3).
Treatment of AML typically consists of three phases: induction, consolidation and
maintenance. Standard-of-care induction chemotherapy ranges from mid-to-high intensity for
patients who can tolerate such doses, or lower-intensity for patients presenting with AML who
cannot tolerate intense chemotherapy regimens. In addition, stem cell transplantation is another
traditional therapeutic method for patients unable to achieve remission using conventional
inductive/consolidative chemotherapy. Consolidation therapy typically consists of mid-to-lower
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intensity chemotherapy. Beyond chemotherapy and stem cell transplantation, targeted
therapies have recently risen to prominence in the treatment of AML as cytogenetic studies and
understanding have improved (1,2). Recent studies from the Cancer Genome Atlas Research
Network (NEJM, 2013) have identified nine functional categories of mutated genes in AML that
have yielded an array of potential therapeutic options. Some of these functional categories
include transcription factor fusions as well as mutations in tumor-suppressor genes and activated
signaling genes (4). For example, aberrant signaling pathway activation is shown to stem from
mutations in the tyrosine kinase receptor FLT3 which is commonly mutated in AML. This finding
has given rise to the study and development of targeted FLT3 inhibitors as a targeted therapeutic
strategy (5).

In more recent years, incredible innovation and the emergence of cancer

immunotherapy has undoubtedly bolstered study in additional potential therapeutic strategies
to combat AML. This work will detail the development of a novel approach towards the
modulation of an immunotherapeutic chimeric antigen receptor for the treatment of AML.

Cancer Immunotherapy
The immune system consists of a robust and intelligent machinery that is subdivided into
two branches: adaptive and innate immunity. Adaptive immunity consists of B- and Tlymphocytes that engage and recognize a foreign antigen and begin mounting an immune
response via clonal expansion over a period of time. Innate immunity consists of a variety of
immune cells, such as natural killer (NK) cells and the various granulocytes, that provide rapid
and continuous assault against foreign pathogens while working in tandem as adaptive immune
response mounts. Together these two branches are critical towards the detection of cancer (6).
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Furthermore, the understanding of these principles allows harnessing and development of
potential immunotherapeutic strategies against cancer.
In the last couple of decades, cancer immunotherapy has certainly progressed to
encompass a large variety of strategies (7). These strategies include the development of monospecific antibodies, bi-specific antibodies, antibody-drug conjugates, chimeric antigen receptor T
(CAR-T) cells, and immune checkpoint blockade therapies. A notable immunotherapy for the
treatment of AML is the antibody gemtuzumab ozogamicin (anti-CD33) conjugated to the drug
calicheamicin for the treatment of CD33-positive AML which has shown treatment improvements
and increased survival (8). Additionally, the targeting of AML by CD123-specific chimeric antigen
receptor therapy has been demonstrated by efficient targeting of CD123+ human AML blasts (9).

Leukemia-Associated Antigen PR1
The benefit of stem cell transplantation is seen in the ability to elicit graft-versus-leukemia
(GvL) effects in patients. These benefits are demonstrated when cytotoxic T lymphocytes (CTL)
from the donor are able to target and destroy leukemic blasts and their progenitors in the
recipient. It is likely that this targeting is achieved via specific CTL interaction with a tumorassociated antigen (10,11). In the case of leukemia and AML, this occurs via recognition of a
related antigen. These related antigens are classified into several categories including antigens
expressed only in leukemia cells (leukemia-specific), those expressed mostly in leukemia cells and
blasts but also in normal cells (leukemia-associated), antigens expressed in germline cells (cancertestis antigens), and those ubiquitously expressed in the body (12). The targeting of these types
of antigens in the setting of cancer immunotherapy has certainly grown and developed over the
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years as our understanding has increased. Furthermore, criteria has been specified by the
Translational Research Working Group of the National Cancer Institute to evaluate worthy
antigens for study (13). This criteria has been further elucidated in the context of leukemia and
AML. These criteria are: demonstrate leukemia specificity, antigen should be frequently found in
leukemia cells and their progenitors, demonstrate an oncogenic role, demonstrate
immunogenicity and ability to cause an immune response, and be clinically relevant (12).
The Molldrem group has focused its study on the leukemia-associated antigen, PR1. PR1
is a human leukocyte antigen (HLA)-A2*01-restricted nonameric peptide (VLQELNVTV) derived
from serine proteases proteinase 3 (P3) and neutrophil elastase (NE) (14). Both P3 and NE are
found as serine proteases within normal azurophilic granules as well as myeloid leukemia blasts.
PR1 has been found to be overexpressed in leukemia blasts and its expression on blasts is
recognized by PR1-specific CTL and results in preferential killing of blasts both in vitro and in vivo
(15,16,17). Furthermore, targeting PR1 by vaccination has also been demonstrated in a Phase
I/II clinical trial by our group and was found to induce antigen-specific immune response
occurring early after vaccination as well as an increase in T cell receptor avidity of PR1-CTL (18).
In a novel therapeutic approach, a T cell receptor (TCR)-like monoclonal antibody named
8F4 (anti-PR1/HLA-A2) was developed against the PR1/HLA-A2 complex. 8F4 has demonstrated
ability to lyse leukemic blasts and progenitors as well as inhibit leukemia progenitors but not
normal, healthy progenitor growth in vitro (19). In vivo models have shown that 8F4 pretreatment prevents AML engraftment, reduces established AML, prolongs survival, and reduces
leukemia-initiating potential in mouse models (20).
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With the success of 8F4, our group has developed additional therapies utilizing
humanized 8F4 (h8F4) such as adaptation into a bi-specific T-cell engaging antibody (h8F4-BiTE)
specific for CD3 which is ubiquitously expressed on T cells and for the PR1/HLA-A2 complex (21).
Additionally, h8F4 has also been developed into a chimeric antigen receptor T cell (CAR-T)
platform (22). As a chimeric antigen receptor therapy, h8F4-CAR shows promise as a very
powerful therapeutic modality for AML. The development of these additional h8F4-bearing
therapies seek to increase the potency of h8F4 against AML. While increasing potency of a
therapy, the potential to increase cross-reactivity and on-target, off-tumor toxicity also occurs.
This work demonstrates the foundational study to maintain specificity of h8F4-CAR against the
PR1/HLA-A2 complex on AML cells while investigating a novel approach to modulate avidity to
decrease potential for cross-reactive and on-target, off-tumor toxicity.

Chimeric Antigen Receptors and Associated Toxicities
Together with rise of immunotherapy as a whole, the study and implementation of
chimeric antigen receptor T (CAR-T) cells as a therapeutic strategy has greatly increased. CAR-T
cells are T lymphocytes genetically engineered to express a single chain fragment variable (scFv)
from an antibody together with costimulatory and signaling moieties of the T cell receptor
complex/co-complex. This engineering creates a chimeric receptor that harnesses the powerful
specificity of B cell receptors or immunoglobulins with the cytotoxic and signaling capabilities of
T cells. CAR-T cells have multiple generations that differ in the number of costimulatory or
signaling domains they have. First generation CAR-T cells typically consist of the scFv, a
hinge/transmembrane domain, and CD3 domain of the TCR/CD3 complex. Second and third
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CAR-T generations consist of the same domains but add one or two additional costimulatory
domains, typically of the associated TCR complex such as CD28 or 4-1BB, respectively. The
addition of more costimulatory and signaling domains to the CAR provides enhanced activation
of the CAR-T cell (6,23,24).
CAR-T cells have primarily shown promising results in the treatment of blood cancers such
as CD19 CAR for the treatment of B-cell acute lymphoblastic leukemia (B-ALL). Brentjens et al.
(2013) demonstrated achievement of durable remissions as well as substantial expansion and
persistence in B-ALL adult patients (25). Furthermore, recent approvals of Kite’s Yescarta
(axicabtagene ciloleucel) and Novartis’ Kymriah (tisagenleucel) by the United States Food & Drug
Administration (FDA) indicate efficacy and potential of CAR-T cell therapies (26). In the setting of
acute myeloid leukemia, CAR-T cell therapy potential is also under investigation. CD33 CAR-T cells
have shown in vitro activity against AML cell lines and primary samples as well as reduction in
leukemia burden and survival advantages in vivo (27). As previously described (22), and shown
below in Figures #1 and 2, to increase the efficacy of the h8F4 antibody, our group has developed
a 2nd-generation chimeric antigen receptor, h8F4-CAR. H8F4-CAR consists of the h8F4 scFv (VH
and VL2 regions), a G4S linker, an IgG1 CH2CH3 extracellular hinge/stem, a CD28 transmembrane
and intracellular costimulatory domain, and a CD3 intracellular signaling domain.
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Figure #1. Linear cassette view of wildtype, unmodified h8F4-CAR.

Figure #1. Linear cassette view of wildtype h8F4-CAR. Sequence begins with a signal peptide
and includes variable light chain 2 and variable heavy chain of the h8F4-CAR scFv linked
together with a G4S linker. Extracellular hinge/stem region of h8F4-CAR consists of IgG1
constant heavy chains 2 and 3. Transmembrane and a portion of the intracellular region
consists of CD28 as well as an fully intracellular CD3 region. Relative positioning for CDR
(complementarity-determining regions), IgG1 CH2 and CH3 regions, transmembrane (TM), and
ITAMs (immunoreceptor tyrosine-based activation motif) locations are specified.

Figure #2. H8F4-CAR interaction with PR1/HLA-A2-expressing AML blast.

Figure #2. General schematic of PR1/HLA-A2-presentation on AML cell surface and interaction
with h8F4-CAR. H8F4-CAR components and relative positioning shown above. H8F4-CAR
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recognizes surface-presented PR1/HLA-A2 on the AML cell surface and can elicit cytotoxic
effects and immune response.

h8F4-CAR maintains recognition of PR1/HLA-A2 and specifically mediates anti-leukemic activity
against PR1/HLA-A2-expressing AML cell lines and primary AML blasts in vitro (22). The benefit
of targeting PR1/HLA-A2 using h8F4-CAR has also been demonstrated by our group in PDX models
where h8F4-CAR can effectively target AML within the central nervous system unlike naked h8F4.
Ultimately, this demonstrates the powerful potential of h8F4-CAR as a CAR-T cell therapy for the
treatment of acute myeloid leukemia.
Unfortunately, CAR-T cell therapies are not without associated toxicities that range in
severity and reversibility that occur in a variety of mechanisms. One of the most common
toxicities seen as a result of CAR-T cell therapy is cytokine release syndrome (CRS). CRS is caused
by large-scale immune activation and release of cytokines as a result of CAR-T therapy. Further,
CRS can result in clinical features like fatigue, nausea, tachycardia, liver failure, hypotension,
myalgia, renal impairment, and overall life-threatening clinical presentations. In addition to
possibility of CRS, CAR-T cell therapy-associated toxicities include neurological toxicity,
anaphylaxis, graft vs. host disease (GvHD), and on-target, off-tumor reactivity (23, 28).
Furthermore, common issues in the field of CAR-T therapies include CAR-T cell exhaustion and
persistence which require innovative strategies to improve (29). In the case of h8F4-CAR, its
target PR1/HLA-A2 is also normally expressed at low-levels on healthy hematopoietic cells but
overexpressed on myeloid leukemia cells. This suggests potential for on-target, off-tumor
toxicity. On-target, off-tumor effects have also been seen in CD19 CAR to treat B-ALL since CD19
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is endogenously expressed on B-cells. On-target, off-tumor toxicity as a result of CD19 CAR has
been shown to result in B-cell aplasia, which is the elimination of both normal and malignant B
cells (24).
Fortunately, there is an assortment of treatments to combat CAR-T cell-related toxicities.
However, many of these therapies are reactive and not proactive. Recent research has shown
promising results in proactive methods to prevent CAR-T cell toxicity such as introduction of a
“suicide” gene to eliminate CAR-T cells within the body should related toxicities become
unmanageable (30). Additionally, methods to introduce temporary, transient CAR-T cell therapy
is also under investigation (31). Because of the known issues surrounding CAR-T cell therapy
toxicity, it is the goal of this work to introduce and detail the initial and on-going development of
a proactive method to prevent or modulate CAR-T therapy in the setting of h8F4-CAR using the
natural genetic code and codon bias. H8F4-CAR represents a prime candidate to study novel and
unique methodologies such this to address cross-reactivity and on-target, off-tumor effects as a
result of potent CAR therapies. As a first-in-class, TCR-like monoclonal antibody adapted in a CAR,
h8F4-CAR is ideal due to its high avidity and potency against the PR1/HLA-A2 complex, which is a
self-antigen. Furthermore, identifying a unique method to improve and enhance h8F4-CAR using
the natural genetic code and codon bias by modulating avidity can hold promise when used in
other CAR platforms or adoptive cellular therapy platforms.
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The Genetic Code, Codon Bias, and Codon Therapeutics
The genetic code consists of the 64 codons that encode for the 20 standard amino acids.
These amino acids serve as the fundamental building blocks of all proteins within our body and
those of most living organisms on Earth. Our genetic code is degenerate and redundant in that
the 20 standard amino acids have between one and six codons that can encode for them at
varying frequencies. The amino acid serine, for example, has six codons that can encode for it.
These six codons are used at varying frequencies within the human genome. This means that of
these six codons, there is one codon that used more often than the others and another codon
that is used the least of all the other codons. This principle is the basis of codon bias. Codon bias
is maintained across codons and has been used as the basis for developing methods to alter rates
of expression to improve therapies. Table #1 provides codon fractions where bias between
codons for amino acids are clearly demonstrated.
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Table #1. Codon usage frequency table for the human genome.
Codon
TTT
TTC
TTA
TTG
TAT
TAC
TAA
TAG
CTT
CTC
CTA
CTG
CAT
CAC
CAA
CAG
ATT
ATC
ATA
ATG
AAT
AAC
AAA
AAG
GTT
GTC
GTA
GTG
GAT
GAC
GAA
GAG

Amino Acid
F
F
L
L
Y
Y
Stop
Stop
L
L
L
L
H
H
Q
Q
I
I
I
M/Start
N
N
K
K
V
V
V
V
D
D
E
E

Fraction
0.45
0.55
0.07
0.13
0.43
0.57
0.28
0.20
0.13
0.20
0.07
0.41
0.41
0.59
0.25
0.75
0.36
0.48
0.16
1.00
0.46
0.54
0.42
0.58
0.18
0.24
0.11
0.47
0.46
0.54
0.42
0.58

Codon
TCT
TCC
TCA
TCG
TGT
TGC
TGA
TGG
CCT
CCC
CCA
CCG
CGT
CGC
CGA
CGG
ACT
ACC
ACA
ACG
AGT
AGC
AGA
AGG
GCT
GCC
GCA
GCG
GGT
GGC
GGA
GGG

Amino Acid
S
S
S
S
C
C
Stop
W
P
P
P
P
R
R
R
R
T
T
T
T
S
S
R
R
A
A
A
A
G
G
G
G

Fraction
0.18
0.22
0.15
0.06
0.45
0.55
0.52
1.00
0.28
0.33
0.27
0.11
0.08
0.19
0.11
0.21
0.24
0.36
0.28
0.12
0.15
0.24
0.20
0.20
0.26
0.40
0.23
0.11
0.16
0.34
0.25
0.25

Table #1. Emboldened and highlighted codons within the table are examples of rare codons
present within the codon populations. These are targeted as rare codons to test and study
their effects and efficiency in sequences and through transcription and translation. Codons such
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as the TCG and CGT codons for serine and arginine, respectively, are more rare in fraction than
other rare codons. Fractions represent usage compared to codons within the pool that encode
for the same amino acid. Further, this translates to lower presence in frequency per thousand
codons (data not shown). Table was adapted and values taken from the GenScript Codon Usage
Frequency Tool.

Existing methodologies utilizing codon bias in therapeutics include codon optimization and codon
modification. Codon optimization involves altering all codons within a sequence, such as the
sequence of a biologic agent or protein, to improve and theoretically maximize biologic/protein
expression. Codon optimization has previously been investigated, such as in gene therapy
research for treatment of hemophilia A by targeting human factor VIII. This investigation studies
the utilization of codon bias to modify codons synonymously into their more commonly used
counterparts based on codon usage tables in order to increase or maximize protein expression.
Deficiency or low expression of human factor VIII is caused by inefficient factor VIII mRNA
expression as well as protein misfolding. Ward et al. (2011) demonstrated that codon
optimization of factor VIII cDNA constructs achieved 29- to 44-fold increase in expression which
shows desirable results to combat human factor VIII deficiency and hemophilia A. These results
demonstrate codon optimization therapy potential (32). The promising effects of codon
optimization has also been demonstrated in adoptive cell therapies such as adoptive T cell
receptor therapy. Scholten et al. (2006) demonstrated marked improvement in functional
expression of transgenic human T cell receptors when the TCR  and  chains were codon-
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optimized compared to wildtype counterparts (33). Advantages of codon optimization have also
been noted in chimeric antigen receptor T cell therapy (34).
Codon optimization is an attractive option to improve biologic therapies. However, in
certain settings, codon optimization may not be the best route to pursue. H8F4-CAR, for example,
may not be the best candidate for codon optimization. As previously mentioned, h8F4-CAR
targets PR1/HLA-A2, a self-antigen overexpressed on myeloid leukemia cells and normally
expressed at low-levels in hematopoietic cells. Codon optimization to maximize h8F4-CAR
expression and efficacy has potential to introduce additional risk of on-target, off-tumor toxicity
to healthy cells. Fortunately, there are other codon therapy strategies. Codon modification
utilizing codon bias provides a unique and novel method to improve both h8F4-CAR and adoptive
cell therapies as a whole. Hoekema et al. (1987) demonstrated in the PGK1 gene of
Saccharomyces cerevisiae that substitution of codons into their rare, or least frequently
abundant, isoform in increasing numbers led to decreased expression of the PGK1 protein. It was
posited that increasing substitutions into rare codons led to impaired elongation due to low tRNA
pools for their cognate rare codon leading to mRNA destabilization and ribosomal pausing. As a
result, PGK1 expression was diminished (35). Utilizing the concept of codon substitution and
modification, this can be applied to find novel and unique methods to improve adoptive cellular
therapy strategies such as CAR-T therapies. Based on this concept and supportive findings, we
decided to apply codon modification and substitution to investigate potential to modulate the
expression and functional avidity of h8F4-CAR for optimal avidity to the PR1/HLA-A2 complex.
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Hypothesis and Specific Aims
We hypothesize that synonymous codon modification of h8F4-CAR to demonstrate
reduced expression against PR1/HLA-A2 may provide a method to allow modulation of functional
avidity of h8F4-CAR. Because PR1/HLA-A2 is a self-antigen expressed on normal hematopoietic
cells but overexpressed on AML cells, the high avidity of h8F4-CAR and its potency has the
potential to cause varying levels of on-target, off-tumor toxicity reducing its therapeutic index.
Synonymous codon modification of h8F4-CAR represents a unique approach and strategy for
modulating the affinity/avidity of CAR therapies by introducing rare synonymous codon changes
to attain an optimal avidity that effectively targets overexpressed antigen on cancer cells and
spares cytotoxic effects on normal cells. In addition, codon modification may also provide a
method to increase persistence and reduce non-specificity of CAR-T therapies. To investigate the
potential and resulting effect of codon modification in h8F4-CAR, the following aims will be
employed:

AIM 1: To develop and construct h8F4-CAR iterations with rare codon modification of
amino acid residues to study whether modification of residues in the IgG1 CH2CH3
domain, CD28 costimulatory domain, and CD3𝜁 signaling domain of h8F4-CAR will alter
h8F4-CAR expression.

AIM 2: To test and determine whether introduced rare codon modification of amino acid
residues within h8F4-CAR will alter h8F4-CAR expression, allow modulation of avidity, and
maintain specificity for the PR1/HLA-A2 complex.
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Our goal is to develop a novel and unique strategy utilizing codon bias and codon
modification as a therapeutic method to improve chimeric antigen receptor T-cell therapies and
adoptive cellular therapies as a whole. This project has the potential to bring forward new
strategies to the design, development, and optimization of CAR therapies not only for the
treatment of AML but other malignancies as well. Modulation of CAR therapies by regulating and
tuning expression and avidity can further improve patient treatment by increasing therapeutic
indices and reducing likelihood of unwanted cytotoxicity.
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Chapter 2: h8F4-CAR Codon Modification
Codon Modification Construct Development
Wildtype, unmodified h8F4-CAR, as described by Ma et al. (2016) and as shown in Figure
#1 was extensively studied at the codon-level to determine possible iterations of h8F4-CAR that
could be developed to study the effects of codon-modification in h8F4-CAR. In order to maintain
h8F4-CAR specificity towards the PR1/HLA-A2 complex in the first phase of codon modification
testing, it was decided to limit codon modifications and substitutions to only the IgG1 CH2CH3
hinge/stem extracellular region, the CD28 transmembrane and intracellular costimulatory
region, and the CD3 intracellular signaling region. Therefore, the initial signal peptide, h8F4 scFv,
and its G4S linker sequence did not feature any codon modifications or substitutions at all.
The three regions that would feature codon modification were analyzed at the codonlevel using codon frequency tables for the human genome to quantify the number of codon
isoforms present for amino acids determined to be best for rare codon substitution and
modification. These amino acids were also determined using a codon frequency usage table.
Table #1 demonstrates the variety in codon usage using a codon frequency table for the human
genome. Using the table, we looked at all 20 standard amino acids that had between two and six
codons that encoded for its cognate amino acid at less than 8% overall frequency per thousand
codons within the human genome compared to its other respective isoforms. This yielded a
variety of potential amino acids and their rare codons that could be used to modify h8F4-CAR.
These included the TCG codon for serine, the GTA codon for valine, the CTA or TTA codons for
leucine, the ATA codon for isoleucine, the CGT codon for arginine, and the ACG codon for
threonine as well as a few others. Once these rare codons for these amino acids were
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determined, they were then studied, analyzed, and quantified across the three regions for
location, density, and distribution. Of these, the rare TCG codon for serine showed good
distribution within the three regions and was not endogenously present within the regions. In
addition, the rare CGT codon for arginine also showed good distribution with the three regions
and was sparingly endogenously present within the regions. The rare TCG and CGT codons for
serine and arginine, respectively, were selected for rare codon modification within the IgG1
CH2CH3 extracellular hinge, the CD28 transmembrane and intracellular costimulatory region,
and the CD3 intracellular signaling region of h8F4-CAR.
After determining which codons would be modified within the h8F4-CAR sequence into
rare codons, several iterations and constructs were created to test the effect of codon
modification in h8F4-CAR in terms of location and density. Six constructs were developed. These
constructs varied by which amino acid was codon-modified (serine, arginine, or a combination of
both), location (both extracellular and intracellular or intracellular only), and density (denser
extracellularly or intracellularly). These constructs were named S30, S7(i), S6(i), R27, R21(i), and
RS30(i). Figure #3 provides a general breakdown of the six constructs as well as relative position
of rare codon modifications for visualization. Nomenclature for these fragments/constructs was
the following: amino acid residue altered, number of codons changed, and whether codon
modification was intracellular-restricted. For example, the RS30(i) construct features both
arginine and serine residues that were codon-modified, 30 total codon modifications, and all
codons modified were completely located within the intracellular regions (i).
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Figure #3. Overview and relative location of codon modifications in six codon-modified h8F4CAR constructs.

Figure #3. General scheme and overview of the six codon-modified h8F4-CAR constructs
compared to wildtype, unmodified h8F4-CAR. Relative location and positions of codons that were
modified into respective rare codons are provided for enhanced visualization.

Methodology
Codon-Modified h8F4-CAR Construction
A “cut-and-paste” method to introduce insert sequences featuring rare codon
modification in the designated regions (IgG1 CH2CH3 stem, CD28, and CD3) was used by taking
wildtype, unmodified h8F4-CAR, removing endogenous regions, and replacing with rare codonmodified insert sequences. The removal of endogenous regions was facilitated by restriction
enzyme digestion. Constructs that featured codon modification across all three regions (S30 and
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R27) were developed using the endogenous BamHI and SphI enzyme digestion sites within h8F4CAR. Constructs that featured codon modification only intracellularly (S7(i), S6(i), R21(i), and
RS30(i)) were constructed using the endogenous NsiI and SphI enzyme digestion sites within
h8F4-CAR.
The sequences for each codon-modified construct were created in silico by modifying the
endogenous serine or arginine codons into their selected rare codon isoform with the online
SnapGene software using template wildtype, unmodified h8F4-CAR sequence. Following in silico
construction, double-stranded sequences were synthesized by Integrated DNA Technologies.
For construction of h8F4-CAR codon-modified constructs, insert gene fragments received
for each construct and wildtype, unmodified h8F4-CAR plasmid was subjected to restriction
enzyme digestion. Wildtype, unmodified h8F4-CAR plasmid was used as vector for plasmid
synthesis by using restriction enzyme sites BamHI and SphI or NsiI and SphI for removal of
endogenous sequence to allow for insertion of codon-modified sequences. Restriction enzyme
digestion using BamHI and SphI sites was done for wildtype, unmodified h8F4-CAR plasmid as
well as received S30 and R27 gene fragments. In parallel, digestion using NsiI and SphI sites was
done for wildtype, unmodified h8F4-CAR plasmid as well as received S7(i), S6(i), R21(i), and
RS30(i) gene fragments. Following vector enzyme digestions, vectors were dephosphorylated to
enhance and increase ligation efficiency to inserts which were not dephosphorylated. All
restriction enzymes and phosphatase were purchased from New England Biolabs. Following
insert and vector digestions and dephosphorylation, samples were run on an agarose gel and
appropriate bands for digested vectors and inserts were excised and extracted. Gel extractions
were completed as instructed using a QIAGEN Gel Extraction Kit (#28706) and quantified.
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Following quantification, vectors and inserts were ligated together. BamHI and SphIdigested wildtype, unmodified vector was ligated to digested S30 and R27 inserts independently.
Likewise, NsiI and SphI-digested wildtype, unmodified vector was ligated to digested S7(i), S6(i),
R21(i), and RS30(i) inserts independently. This essentially allowed a “cut-and-paste” method of
replacement for endogenous IgG1 CH2CH3 hinge, CD28, and CD3 regions with codon-modified
IgG1 CH2CH3 hinge, CD28, and CD3 regions. Ligation mixtures were mixed and allowed to ligate
overnight for prolonged ligation reaction time.

Prokaryotic Plasmid Synthesis
Following ligation, constructs were transformed into Stbl3 chemically competent
Escherichia coli cells (Invitrogen) as instructed (#C7373-03). Cells were streaked onto agar plates
treated with carbenicillin for selection of successful transformants. Up to 10 colonies were picked
per transformation and placed into bacterial culture tubes with carbenicillin-treated LB broth and
grown overnight. After overnight culturing, a portion of each culture was prepared and plasmid
purified using the QIAGEN QIAPrep Spin Miniprep Kit according to manufacturer’s instructions
(QIAGEN #27106). Diagnostic enzyme digestion was done on samples to assess whether there
was successful insertion of product based on molecular weight. Samples/plasmids determined to
be successfully transformed were then sent to the MD Anderson Advanced Technology Genomics
Core Facility for sequencing using the following primers.
•

h8F4-CAR Vector 5’ primer: 5’ AGACGGCATCGCAGC

•

h8F4-CAR Upstream CH2 primer: 5’ TTTACTGGGGCCAAGG

•

h8F4-CAR CH2 primer: 5’ GAGCCCAAATCTCCTG
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•

h8F4-CAR SFG 3’ primer: 3’ AACTAGAGCCTGGACC

Once sequences were returned, sequences were analyzed and aligned with their respective
templates using the online SnapGene software. Additionally, they were cross-checked using the
sequences returned from all primers for a given prep to produce a continuous sequence and
verification of a flawless sequence.

Figure #4. Stepwise schematic of prokaryotic plasmid synthesis.

Figure #4. Stepwise schematic of prokaryotic plasmid synthesis. Following successful ligation of
codon-modified h8F4-CAR plasmids, plasmids were transformed and grown in chemically
competent E. coli cells. Between plasmid mini- and maxi-preps and in conjunction with
sequencing, plasmid preps were also subjected to diagnostic restriction enzyme digestion.

Following identification and verification of flawless sequences for a plasmid prep, the
remaining stored bacterial culture was grown at a large-scale for greater isolation and
purification of plasmid. These cultures were then used to prepare and purify plasmid maxiprep
to be able to begin producing virus. Plasmid maxiprep was prepared using the Plasmid Plus
Maxiprep Kit as instructed by manufacturer (QIAGEN #12963), quantified, and brought to a
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standard concentration and stored until further use. Following production and purification of
larger-scale plasmid quantities, codon-modified h8F4-CAR constructs were prepared for
retroviral packaging for transduction into cells. Stepwise schematic for prokaryotic plasmid
synthesis is shown in Figure #4.

Retroviral Packaging of Codon-Modified Constructs
Using plasmid maxipreps with confirmed flawless sequences for each h8F4-CAR codonmodified construct, each construct was packaged into a retroviral system for viral transduction
into cells. 293GP cells were used for retroviral packaging. Cells were seeded onto plates and
transfected by way of lipofection. Lipofection consisted of two separate reactions. One reaction
contained Lipofectamine 2000 reagent (Invitrogen #11668-019) and Opti-MEM medium (Gibco
#31985-062). The second reaction contained plasmid of interest for transfection (each h8F4-CAR
construct), viral helper plasmid (RD-114 envelope), and Opti-MEM medium. Both reactions were
mixed together and incubated briefly before conducting lipofection and incubating for a 6 hour
period. Following lipofection, viruses were harvested three times by collecting culture
supernatant and replacing with fresh 293GP culture medium. 293GP culture medium consisted
of DMEM High Glucose medium (GE HyClone #SH30022.01) supplemented to 10% with heatinactivated fetal bovine serum (Corning #35-010-CV) and to 1% with penicillin/streptomycin
solution (GE HyClone #SV30010). Harvested viral supernatant was removed of packaging cells
and debris and supernatants were stored until further use.
Once retroviral supernatants were collected, supernatants were then titrated to
determine physical viral titers (virus particles per milliliter – VP/mL) prior to transducing into a
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cell line. Retroviral supernatant collections were titrated using the Cell Biolabs QuickTiter
Retrovirus Quantitation Kit as instructed (Cell Biolabs #VPK-120) and quantified. Table #2 shows
the results of physical virus titration in virus particles per milliliter (VP/mL). Infectious titer is
predicted to be 100 to 1000 of physical viral titer. Because physical virus titers were similar in
order of magnitude, this suggested that when transduced into cells, similar transduction
efficiency was anticipated across the cultures.
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Table #2. Physical virus titers for h8F4-CAR unmodified and codon-modified packaged
retroviruses.
PHYSICAL VIRUS TITER
(VP/mL) - virus particles/mL
Construct

Virus titer (VP/mL)

h8F4-CAR Wildtype

8.869 x 1014

S30

3.942 x 1013

S7(i)

4.426 x 1013

S6(i)

6.029 x 1013

R27

5.934 x 1013

R21(i)

6.671 x 1013

RS30(i)

4.159 x 1013

Table #2. Summarization of physical virus titers for h8F4-CAR constructs. Physical virus titers
were quantitated using retroviral RNA from each retrovirus isolated and purified from the Cell
Biolabs QuickTiter Retrovirus Quantitation Kit (Cat# VPK-120).
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Chapter 3: Codon-Modified h8F4-CAR Transduction into Jurkat Cells as
A Model System
Retroviral Transduction of h8F4-CAR constructs into Jurkat Cells
Following retroviral packaging and titration, retroviruses harboring h8F4-CAR codonmodified constructs were then prepared for transduction into a mutant Jurkat cell line (J.RT3T3.5) deficient of T cell receptor (TCR)  chain, hereby referred to as Jurkat -. TCR  chain
deficiency renders the cells to lack endogenous TCR complex. Because CAR-T cells are TCRindependent, this cell line served as a beneficial model cell line to begin testing codon-modified
h8F4-CAR constructs. The retroviral transduction process is schematically shown in Figure #5.

Figure #5. Stepwise schematic process of retroviral transduction and culturing.

Figure #5. Stepwise process of retroviral transduction of h8F4-CAR codon-modified constructs
into Jurkat - cells is schematically demonstrated above. Prior to treatments and addition during
day zero steps, RetroNectin pre-treatment, culture medium treatment, and retroviral
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supernatant treatments were all aspirated before addition of next treatment. Plates and flask are
not drawn to scale and are meant for visualization purposes.

Methodology
Transduction Process
Retroviral transduction consisted of multi-day preparation and following day 0 of
transduction, required careful culturing as well as a time course study. Since the Jurkat - cell line
does not require activation nor stimulation, pre-transduction preparation consisted of coating
RetroNectin reagent (Takara #T100A) in a non-tissue culture plate with sterile PBS (Lonza #17516F). RetroNectin coating allows for co-localization of cells and virus during the transduction
process to improve transduction efficiency. Since wildtype, unmodified h8F4-CAR and the 6
codon-modified h8F4-CAR constructs were transduced, 7 wells were prepared and coated with
RetroNectin as well as 1 additional well to serve as a mock/non-transduced control well for mocktransduced cells. Thus, 8 total wells were coated and prepared for transduction. Following
coating, the plate was sealed and placed at 4oC overnight to allow for coating of wells.
The following day, day 0 of transduction, the RetroNectin-coated plate was allowed to
acclimate to room temperature and RetroNectin solution was aspirated and replaced with
complete culture medium consisting of RPMI 1640 medium (GE HyClone #SH30255.01) with 10%
concentration of heat-inactivated fetal bovine serum (Corning #35-010-CV) and 1%
concentration of penicillin/streptomycin solution (GE HyClone #SV30010). After addition of
complete medium, the plate was placed in incubator for a brief incubation. During this time,
titrated retroviral supernatants were thawed and brought to room temperature. Following
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incubation, complete culture medium was aspirated and retroviral supernatant of respective
h8F4-CAR codon-modified construct viral supernatant was added. For the mock/non-transduced
control well, complete culture medium was added in lieu of retroviral supernatant. The plate was
sealed and centrifuged at room temperature at 2000g for 90 minutes. During centrifugation,
cultured Jurkat - cells for transduction were counted, pelleted, and resuspended in fresh
complete culture medium at 150,000 cells per milliliter. Following centrifugation, retroviral
supernatants were aspirated and discarded appropriately and replaced with Jurkat - cell
suspension to 300,000 cells per transduction/well. The plate was re-sealed and centrifuged at
1000g for 30 minutes before placing in an incubator to begin culture.
At day 2 of transduction, half of existing medium in transduced cultures was removed and
replaced with fresh complete medium. At day 3, the cells were removed from the RetroNectincoated, non-tissue culture plate and counted. Cells were resuspended in complete medium and
placed in 12-well tissue-culture-treated plates. Cells were counted every other day until day 7
and gradually scaled to larger culturing vessels such as 6-well tissue-culture-treated plates and
T25 flasks. At day 7, cells were counted and an aliquot of culture was removed and prepared for
transduction efficiency and analysis by flow cytometry.

Flow Cytometry Preparation and Staining
Following seven days after transducing h8F4-CAR unmodified and codon-modified
constructs into Jurkat - cells, 2 million cells from each culture were removed and prepared for
staining and analysis by flow cytometry. This included cells from each culture: unmodifiedwildtype h8F4-CAR, S30, S7(i), S6(i), R27, R21(i), RS30(i), and control (mock-transduced) cultures.
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Following removal from culture, cells were washed, centrifuged, and pelleted. Washed cells were
resuspended using 250L PBS to make 5 aliquots of 400,000 washed cells into independent FACS
tubes to begin staining. Staining was split into five tubes per sample group including: a tube each
for unstained sample, fluorescence-minus-one (FMO) stained sample, PR1/HLA-A2 tetramer
(phycoerythrin (PE)-conjugated) stained sample, pp65/HLA-A2 tetramer stained sample (PEconjugated) which served as an irrelevant control peptide stain, and Jackson ImmunoResearch
goat anti-human IgG (H+L) F(ab’)2 fragment antibody (#109-006-088) stained sample (Alexa Fluor
647-conjugated) which binds to the hinge/stem region of h8F4-CAR. Each sample, except
unstained samples, were also stained with Ghost Violet 510 viability dye (Tonbo #13-0870-T100)
for live cell gating. Following incubation, cells were washed to remove excess antibody/tetramer,
resuspended, fixed and stored until run on a BD LSR Fortessa cytometer.

Fluorescence-Activated Cell Sorting
Following day seven post-transduction flow cytometric analysis of surface expression and
flow cytometry, cells were grown for another seven days and prepared for sorting into three
populations using PR1/HLA-A2 tetramer. The three populations consisted of cells positive at a
high avidity, positive at an intermediate avidity, and negative. 30 million cells were prepared for
sorting from each sample group (S30, S7(i), S6(i), R27, R21(i), RS30(i), and unmodified) by
washing, centrifuging, and pelleting cells. Cells were resuspended, strained, and stained with
viability dye for live cell gating and PR1/HLA-A2 tetramer conjugated to phycoerythrin (PE) for
sorting. After incubation, cells were washed twice to remove excess tetramer or viability dye and
run through a cell strainer once more before resuspending cells. Cell sorting was performed by
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the MD Anderson Advanced Cytometry & Sorting South Campus Core Facility. Sorting schemes
are shown in Figure #7. After sorting, cells were centrifuged, pelleted, and resuspended in
complete culture medium and maintained for two weeks to allow cells to recover viability and
proliferate.

Day 7 Analysis of Transduced h8F4-CAR Cells Reveals Similar CAR Surface Expression
Analysis of samples run on cytometer revealed varying degrees of h8F4-CAR surface
expression across all sample groups (S30, S7(i), S6(i), R27, R21(i), RS30(i), and unmodified). As
expected, no surface expression of h8F4-CAR was detected in mock-transduced control cells.
Surface expression was determined by percentage of positive binding of sample groups using PR1
tetramer as the direct antigen of h8F4-CAR and also anti-human IgG (H+L) F(ab’)2 fragment
antibody which binds to the IgG1 CH2CH3 extracellular hinge/stem of h8F4-CAR. In addition,
surface expression is further indicated by MFI (median fluorescence intensity) values of sample
groups using these two staining agents. Percentage positive for binding as well as MFI values are
shown in Figure #6. pp65/HLA-A2 tetramer was used as an irrelevant peptide control against
h8F4-CAR and showed low levels of positive binding to h8F4-CAR constructs (data not shown).
This can be explained as h8F4-CAR binds pp65/HLA-A2 peptide and tetramer in the context of
HLA-A2 as part of its conformational epitope. pp65 peptide antigen is present as a result of
cytomegalovirus (CMV) infection also in the context of HLA-A2 (35). PR1/HLA-A2 tetramer
positive binding to h8F4-CAR constructs varied between 53.3-89.4% with less than 0.01% positive
binding to mock-transduced cells. Anti-human IgG (H+L) antibody percentage positive binding to
h8F4-CAR constructs varied between 52.3-89.3% with 0.16% positive binding to mock-
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transduced cells. Surface expression variation across the h8F4-CAR constructs may be due to
codon modification or as a result of transduction efficiency.

Figure #6. h8F4-CAR surface expression at day seven post-transduction using PR1 tetramer and
anti-IgG (H+L) antibody that binds to h8F4-CAR stem.

Figure #6. h8F4-CAR surface expression at day seven post-transduction. Surface expression
visualized varies across the different h8F4-CAR constructs both unmodified and codon-modified.
Values are shown as both percentage and median fluorescence intensity (MFI) values.

Flow Cytometric Surface Expression Patterns Remain Consistent and Indicates Effects of Rare
Codon Modification
Sorting was conducted in order to further indicate the effects of rare codon modification
by obtaining and studying purified populations. Once purified populations were obtained, deeper
analysis could be conducted to test and study the effects of rare codon modification in h8F4-CAR
compared to unsorted data obtained at the seven day post-transduction timepoint. This further
analysis allows study of whether rare codon modification alters expression of h8F4-CAR as well
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as potentially reveal effects of rare codon modification previously unseen at the seven day posttransduction timepoint. Additionally, sorting of these constructs into purified populations can
further indicate rare codon modification effects on surface expression compared to unsorted
populations which may be altered as a result of transduction efficiency.

Figure #7. Sorting scheme for PR1/HLA-A2 tetramer sorting of codon-modified constructs.

Figure #7. Sorting scheme for PR1/HLA-A2 tetramer sorting of codon-modified constructs.
Sorting scheme and gating seen was maintained across sorting for all codon-modified constructs.
High, intermediate, and negative populations were selected in order to study different avidities
to PR1/HLA-A2 tetramer via additional assays.
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Figure #8. Percentage positive binding and MFI values of sorted h8F4-CAR constructs at two
weeks post-sort.

Figure #8. Percentage positive binding and MFI values of sorted h8F4-CAR constructs using
PR1/HLA-A2 tetramer and human anti-IgG (H+L) which binds to the hinge/stem region of h8F4CAR. PR1/HLA-A2 tetramer staining of high positive (A), intermediate positive (C), and negative
(E) populations. Human anti-IgG (H+L) for h8F4-CAR hinge/stem binding stains of high positive
(B), intermediate positive (C), and negative (F) populations. Cells were analyzed at these
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timepoints to study whether h8F4-CAR cells persist and if expression changes over extended
periods of time.

Day 7 post-transduction and two-week post-sorting timepoints were selected for two
reasons. First, preliminary evaluation of h8F4-CAR surface expression at day 7 post-transduction
would allow early identification of transduction success and efficiency. Second, analysis of cells
two weeks post-sorting would allow assessment whether cells had continued expression of h8F4CAR both persisted and was stable as well as verification of whether cells were indeed purified
based on the sorting scheme.
Flow cytometry analysis of samples from two-week post-sorting timepoint revealed
similar pattern of expression across sorted h8F4-CAR constructs that was seen in unsorted
constructs. Percentage positive binding as well as MFI values are shown in Figure #8. This was
notably indicated where the same constructs that exhibited a higher percentage positive and MFI
value in the day seven post-transduction and unsorted flow cytometry analysis continued this
same trend in the two week post-sort flow analysis. These trends revealed that surface
expression did indeed vary across the different h8F4-CAR constructs. It is still possible that these
variations occur as a result of transduction efficiency or codon modification. Since this timepoint
studied cells that were sorted in purified populations, it is less likely that surface expression
differences are a result of transduction efficiency and more indicative of the effects of rare codon
modification. While retrovirus titration suggested theoretically that similar retrovirus physical
titers would result in similar transduction efficiency, each experiment varies. Furthermore,
different cell lines can also contribute to different infectious retroviral titers. Additionally, it is
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possible and more likely that codon modification may be the cause of varying levels of surface
expression. Deeper analysis of these constructs would certainly assist in elucidating this
possibility. Therefore, additional experiments were performed such as immunoblotting.
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Chapter 4: Immunoblotting of Codon-Modified h8F4-CAR Constructs
Protein Extraction from h8F4-CAR-Transduced Cells
Following flow cytometric analysis of codon-modified h8F4-CAR surface expression,
differences of expression could also be studied using immunoblotting antibodies for h8F4-CAR.
While flow cytometry can provide a first-look at surface expression following introduction of rare
codon modification, immunoblotting can further elaborate and identify any potential effects that
cannot be detected by flow cytometry by studying total protein and not what is only expressed
at the cell surface. This included lysing of cells for protein isolation to conduct immunoblotting.
Following transduction of h8F4-CAR codon-modified constructs into the mutant Jurkat cell line,
Jurkat -, cells were analyzed by flow cytometry for surface expression as seen in the previous
chapter and in Figures #6 and 8. At the same timepoints cells were analyzed for surface
expression by flow cytometry, cells were also lysed to conduct immunoblotting for h8F4-CAR.
Immunoblotting was conducted to examine whether codon modification alters h8F4-CAR
expression at the protein-level that could not be detected by flow cytometry.

Methodology
Cell Lysis & Protein Extraction
To lyse cells and isolate protein from transduced h8F4-CAR cells, cells were collected,
washed thoroughly, and pelleted. Cells were resuspended in cell lysis buffer (consisting of
10mM/L HEPES (pH 7.9), 10mM/L KCl, 0.1mM/L EGTA, 0.1mM/L EDTA, 2mM/L DTT)
supplemented with protease inhibitor (Thermo Scientific #78430) to prevent protease activity.
Cells were thoroughly mixed and vortexed with lysis buffer, centrifuged to remove cell debris,
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and supernatant (whole cell lysate) was collected and quantified. Whole cell lysate was quantified
using the BioRad DC Protein Assay as instructed by manufacturer (BioRad #5000116). Quantified
lysate was then used to conduct immunoblotting to probe for codon-modified h8F4-CAR. Cell
lysates were used for immunoblotting assays for comparison with flow cytometry data. Both of
these timepoints contained cells analyzed by flow cytometry from the same timepoints as seen
in Figures #6 and 8.

Gel Electrophoresis and Immunoblotting
Following quantification, lysates were mixed with prepared denaturing loading buffer,
briefly boiled, and loaded onto pre-cast protein gels (BioRad #456-1094) for electrophoresis using
denaturing running buffer (BioRad #161-0772). Samples were electrophoresed and gel contents
were transferred to PVDF membranes using the BioRad Trans-Blot Turbo RTA Transfer PVDF Kit
and System as instructed by manufacturer (BioRad# 170-4272). Once transferred, membranes
were blocked in blocking buffer (dry 5% non-fat milk in 1% TBS-Tween solution) for one hour
before incubating in the following antibodies independently in blocking buffer overnight. Primary
antibodies included:
•

rabbit anti-human IgG antibody with predicted binding to h8F4-CAR IgG1 hinge/stem
region (Abcam #ab109489) used at 1:250 dilution

•

rabbit anti-human CD28 antibody with predicted binding to h8F4-CAR CD28 region (Cell
Signaling #38774S) used at 1:500 dilution

•

mouse anti-human CD3 antibody with predicted binding to h8F4-CAR CD3 region (Santa
Cruz Biotechnology #sc-166435) used at 1:500 dilution
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•

mouse anti-human actin monoclonal antibody as a loading control (Millipore
#MAB1501R) used at 1:2500 dilution

•

goat anti-human IgG (H+L) AffiniPure F(ab’)2 fragment antibody with predicted binding to
h8F4-CAR IgG1 hinge/stem region (Jackson ImmunoResearch #109-006-088) used at
1:250 dilution

Figure #9. Overview of relative predicted antibody recognition regions for primary
immunoblotting antibodies used.

Figure #9. Predicted binding regions are shown in figure. Rabbit anti-human IgG antibody and
mouse anti-human CD3 antibody have general predicted binding regions as specified by
manufacturer. Goat anti-human IgG F(ab’)2 fragment antibody is a polyclonal antibody and rabbit
anti-human CD28 antibody is a monoclonal antibody that binds endogenous total human CD28
as well as multiple CD28 isoforms.
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Each primary antibody was independently incubated overnight with the exception of anti-actin
primary antibody. Depending on host species of primary antibodies, secondary antibodies were
used for detection of protein bands. Secondary antibodies included:
•

goat anti-rabbit IgG HRP-linked antibody (Cell Signaling #7074S)

•

horse anti-mouse IgG HRP-linked antibody (Cell Signaling #7076S)

•

mouse anti-goat IgG HRP antibody (Santa Cruz Biotechnology #sc-2354)

All secondary antibodies were used at 1:1000 dilutions. Following overnight primary antibody
incubation, membranes were washed thoroughly before incubating with secondary antibody in
blocking buffer for one hour. Membranes were washed thoroughly again before developing using
the Western Lightning Plus-ECL Kit (PerkinElmer #NEL103001EA) as instructed by manufacturer.
Membranes were imaged using a BioRad ChemiDoc Touch Imaging System (Hercules, CA).
Following each imaging of a membrane with a primary antibody (except actin) to detect h8F4CAR, membranes were thoroughly washed and stripped of antibody using Restore Western Blot
Stripping Buffer (Thermo Scientific #21059) according to manufacturer’s instructions. Following
membrane stripping, membranes were re-probed overnight with anti-actin primary antibody in
blocking buffer, incubated in secondary antibody in blocking buffer for one hour, developed, and
imaged with thorough washes in-between. Immunoblotting with anti-actin antibody after
stripping membrane of previous primary antibody allowed verification of similar lysate loaded
onto each gel as a loading control.
Lysates prepared at day 7 post-transduction were blotted following the steps previously
mentioned with 50g lysate per h8F4-CAR sample group (unmodified, S30, S7(i), S6(i), R27,
R21(i), RS30(i), and mock-transduced/control). Each immunoblot was freshly done for each
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primary antibody with the exception of anti-actin primary antibody which was done on same
immunoblot after stripping to verify loading of sample as a control.

Immunoblotting Reveals Altered Expression of Codon-Modified h8F4-CAR
Day 7 post-transduction lysates were immunoblotted using each primary antibody in
order to identify correct molecular weight bands for h8F4-CAR which has a molecular weight of
73kDa. Figure #10A shows immunoblotting for h8F4-CAR samples at day 7 post-transduction
using primary rabbit anti-human IgG antibody which is predicted to bind to the IgG1 hinge/stem
region of h8F4-CAR. Visualization of bands at correct molecular weight for h8F4-CAR confirm
presence of h8F4-CAR as expected. However, interestingly, novel and unique bands in the S30
and R27 groups were visible at about 30kDa which were not present in unmodified, wildtype
h8F4-CAR nor mock-transduced cells which serve as positive and negative controls, respectively.
Presence of these novel bands in codon-modified constructs with rare codon modification spread
extracellularly, transmembrane, and intracellularly indicate that codon modification may indeed
result in a change in protein translation. Immunoblotting results for CD3 are seen in Figure #10B
and show the correct molecular weight for h8F4-CAR across all transduced samples at 73kDa as
well as endogenous CD3 which is naturally found in all T cells, including Jurkat - cells.
Endogenous CD3 bands can be visualized across all samples as a dimer at 34kDa and as a
monomer at 17kDa. It should be noted that the novel, unique bands seen in Figure #10A are not
visualized in Figure #10B. The predicted binding epitope for the anti-CD3 antibody lies at the Cterminal end of the h8F4-CAR-encoding sequence, therefore it may be a result of codon
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modification causing pre-mature translational pausing and stop. This is discussed in greater detail
in Chapter 5 of this thesis.

Figure #10. Immunoblotting of h8F4-CAR constructs at day 7 post-transduction.

Figure #10. (A) Immunoblotting of sample groups at day 7 post-transduction using primary antihuman IgG antibody predicted to bind to IgG1 hinge/stem region of h8F4-CAR reveals expected
bands signifying h8F4-CAR expression at 73kDa, but also reveals novel and unique bands (boxed
in red) suspected to be a result of rare codon modification. (B) Immunoblotting of same groups
at same timepoint using primary anti-human CD3 antibody predicted to bind to CD3 region of
reveals expected bands but no novel/unique bands. Predicted binding region for this antibody
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lies at the C-terminal end of sequence suggesting that some h8F4-CAR translational products
result in pre-mature truncation.

Following sorting and flow cytometric analysis of sorted h8F4-CAR sample groups two
weeks post-sorting (seen in Figures #7 and 8), these same cells from the same timepoint were
also examined in greater detail via immunoblotting. Lysates prepared two weeks post-sorting
were electrophoresed and blotted as previously described. Samples were split across three
gels/membranes since sample groups consisted of unmodified, S30, S7(i), S6(i), R27, R21(i), and
RS30(i) h8F4-CAR constructs that were sorted high positive, intermediate positive, and negative
populations. Figure #11 shows membranes immunoblotted with rabbit anti-human IgG antibody
revealing expected bands for h8F4-CAR at 73kDa as well as previously seen unique bands in
constructs S30 and R27 at about 30kDa. A new set of novel bands is also visualized in constructs
S30 and R27 at about 45kDa. Additionally, a novel band appears in the RS30(i) high positive sorted
population at about 55kDa that was previously not detected. Immunoblotting using anti-human
IgG (H+L) F(ab’)2 fragment antibody which is also predicted to bind to the h8F4-CAR IgG1
hinge/stem region reveals novel bands once again appear at the same molecular weights. This
additional primary antibody probing h8F4-CAR across samples provides corroboratory evidence
that indeed these novel and unique bands appear in codon-modified h8F4-CAR constructs as
shown in Figure #12. These bands also appear most often in the S30 and R27 constructs with
larger numbers of rare codon modification spanning the extracellular, transmembrane, and
intracellular regions of the CAR sequence. Two unique bands also appear in the S7(i) high positive
sorted populations at about 45kDa and another band at about 55-60kDa. While discussed in
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greater detail in Chapter 5 of this thesis, previous studies investigating the role, usage and
substitutions of codons within a sequence have yielded a variety of results and hypotheses
suggesting that codon usage and selection have a variety of effects on translation of a sequence
(32-35). Substitution of more commonly used codons in a sequence (optimization) has been
shown to improve and maximize translation and expression. Substitution of rarer, less frequently
used codons (modification) has been shown to cause translational inefficiencies. These
inefficiencies are expected to be as a result of a myriad of mechanisms and effects such as
ribosomal pausing, pre-mature truncation, and mRNA destabilization (37,38).
When blotted with anti-human CD28 and anti-human CD3 predicted to bind to h8F4CAR CD28 and CD3 regions, no novel bands were detected as shown in Figures #13 and 14.
Endogenous CD3 can be seen as a dimer at 34kDa and as a monomer at 17kDa in Figure #13 and
endogenous CD28 can be seen at about 39-40kDa in Figure #14. It is suspected that codon
modification of h8F4-CAR results in defective translation with premature translational halting
before translating regions where predicted binding epitopes are located. Additionally,
endogenous CD28 and CD3 bands at molecular weights similar to those seen using anti-IgG
antibodies may mask unique band appearance. All novel bands appear selectively in these codonmodified h8F4-CAR iteration groups and were not seen in either unmodified, wildtype h8F4-CAR
nor in negative sorted populations suggesting that these unique bands were likely a result of
codon modification in h8F4-CAR.
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Figure #11. Immunoblotting of h8F4-CAR constructs at two weeks post-sorting using antihuman IgG antibody.

Figure #11. Immunoblot of sample groups at two weeks post-sorting using primary rabbit antihuman IgG antibody predicted to bind to IgG1 hinge/stem region of h8F4-CAR. Immunoblot
reveals novel bands in codon-modified S30 and R27 constructs suggesting codon modification
does alter h8F4-CAR expression. The appearance of these new and unique bands in the S30, R27,
and RS30(i) constructs are in concordance with findings found in Hoekema et al (1987) where
increasing numbers of rare codon substitutions in the PGK1 sequence in S. cerevisiae led to
altered expressed of the cognate PGK1 protein. “H+” refers to cells sorted high positive, “I+”
refers to cells sorted intermediate positive, and “Neg” refers to cells sorted as negative to
PR1/HLA-A2 tetramer.
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Figure #12. Corroboratory immunoblot evidence of codon modification effects altering h8F4CAR expression.

Figure #12. Immunoblot of sample groups at two weeks post-sorting using primary anti-human
IgG (H+L) F(ab’)2 fragment antibody which is also predicted to bind to the h8F4-CAR IgG1
hinge/stem region. Data reveals corroboratory evidence of novel and unique bands in codonmodified constructs suggesting codon modification alters h8F4-CAR expression. Appearance of
novel bands in the same constructs (S30 and R27) provide additional evidence of altered protein
expression as a result of rare codon substitution. Appearance of novel and unique bands in the
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S7(i) construct provide evidence that small numbers of codon modification intracellularly may
also cause translational defectiveness but requires additional study.

Figure #13. CD3 immunoblotting of h8F4-CAR constructs at two weeks post-sorting.
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Figure #13. Immunoblot of sample groups at two weeks post-sorting using primary anti-human
CD3 antibody predicted to bind to CD3 region of h8F4-CAR. Immunoblots do not reveal
presence of novel bands seen in anti-IgG immunoblots suggesting that codon modification results
in defective translation and pausing prior to reaching predicted binding sequence for this
antibody.
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Figure #14. CD28 immunoblotting of h8F4-CAR constructs at two weeks post-sorting.

Figure #14. Immunoblotting of h8F4-CAR sorted populations using anti-CD28 antibody predicted
to bind to CD28 region of h8F4-CAR. Blotting reveals correct bands for h8F4-CAR at 73kDa and
shows endogenous CD28 across samples at 39-40kDa. Additional isoforms of CD28 are predicted
to be bands between 40-70kDa as a result of alternative splicing according to manufacturer. It is
again suspected that lack of novel/unique bands may be due to defective translation that halts
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prior to reaching the antibody recognition portion of this antibody, or if there are indeed novel
bands present, they are masked by endogenous CD28 and its isoforms.
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Chapter 5: Discussion and Future Directions
Advances in the field of cancer immunotherapy for the treatment of a variety of cancers
such as acute myeloid leukemia have been previously demonstrated (8,9). In particular, chimeric
antigen receptor therapies against leukemias have shown success in pre-clinical studies treating
AML and greater success in the clinic against B-ALL (22-27). This work presents foundational
investigations into the improvement and optimization of a chimeric antigen receptor therapy for
the treatment of PR1/HLA-A2+ malignancies. Furthermore, the implications of improving a
therapy by the means presented in this work may hold utility and promise in the setting of CART cell therapies as well as adoptive cellular therapies for a range of malignancies.
The ability to utilize genetic code degeneracy and codon bias has been demonstrated
previously to develop and improve therapies for a variety of maladies (32-34). Two ways of
utilizing the genetic code is codon optimization and codon modification. Codon optimization is
the modification and substitution of codons within a sequence into their other codon
counterparts that encode for the cognate amino acid at a higher frequency/fraction. Optimizing
a sequence has been suggested to maximize and optimize output and expression of its cognate
product (37). Codon modification is the modification and substitution of codons within a
sequence into their other codon counterparts that encode for its cognate amino acid at a variety
of frequencies to potentially tune output and expression of its product. The genetic code and its
inherent codon bias holds potential to improve therapies that require tuning in order to optimize
their function.
In the case of chimeric antigen receptor therapies, a common adverse effect of these
therapies is unwanted on-target, off-tumor toxicity (28). This occurs when the target of a CAR-T
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cell therapy is expressed both in normal and malignant cells and the therapy eliminates both
instead of only malignant cells. When treating B-ALL using CD19 CAR-T cell therapy, on-target,
off-tumor effects have been seen by targeting of CD19-expressing malignant cells and also
healthy CD19-expressing cells resulting in B cell aplasia, or eradication (24,25,28). In cases like
this, a solution is required. In this case, codon optimization in which protein/biologic expression
is optimized and maximized, may be counterproductive and detrimental. However, utilizing rare
codon modification to find unique modalities to tune and circumvent increased potential for ontarget, off-tumor toxicity may provide a proactive technique to improve therapies. This work
details the foundational studies applying the concept of codon modification into a chimeric
antigen receptor therapy.
In this study, we investigated genetic code degeneracy and codon bias in a 2nd generation
chimeric antigen receptor named h8F4-CAR which targets PR1/HLA-A2-expressing blasts (17).
This was investigated by strategically introducing rare codons into the sequence to determine
whether this would alter CAR expression, retain specificity, and identify a manner in which
avidity/affinity of the CAR could be modulated. A codon usage frequency table for the human
genome was used to investigate, identify, and study rare codons present with the human
genome. Once these were determined, they were studied within h8F4-CAR for location, density,
and frequency. The rare codons TCG and CGT for serine and arginine, respectively, were selected
and endogenous codons within specified regions of h8F4-CAR were modified and substituted into
these rare codons. Because there are a variety of permutations in which codon modification
could be applied to h8F4-CAR, six constructs were developed to study some of these
permutations such as location (extracellular, transmembrane, or intracellular), density (more
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dense in a given location), or amino acid (15+ amino acids each with their own rare codon(s)).
The six constructs are shown schematically in Figure #3.
Results from a four-week time course study following transduction of the six constructs
as well as unmodified, “wildtype” h8F4-CAR post-transduction in the mutant Jurkat cell line
(Jurkat -) show that surface expression varies between constructs but is stable and persists.
Varied surface expression may be attributed to two possible factors. The first is that transduction
efficiency varied between the constructs. However, physical viral titration of the viral
supernatants used to transduce the cells revealed similar titers which suggest similar
transduction efficiency. Additionally sorting into pure populations makes the rationale for
transduction efficiency causing the difference in surface expression less likely. The second, and
most likely, is that codon modification may be a cause of varied surface expression. While
expression was varied, percentage positive for either PR1/HLA-A2 tetramer or anti-IgG antibody
which binds to the h8F4-CAR hinge/stem as well as MFI values show that the variation is subtle
between groups. Groups were loosely classified into serine-modified constructs (S7(i), S6(i), and
S30) and arginine-modified constructs (R21(i), RS30(i), and R27). The RS30(i) construct was
grouped with the arginine-modified constructs since the majority of codons modified were
arginine (21 codons) compared to serine (9 codons). In the serine-modified constructs, MFI for
each construct was similar or higher compared to wildtype, unmodified h8F4-CAR. In the
arginine-modified constructs, MFI for each construct was similar or reduced compared to the
wildtype. Consistency in results between both timepoints by flow cytometry supports that rare
codon modification alters surface expression. However, additional methods to detect differences
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in h8F4-CAR expression such as immunoblotting were conducted and indeed revealed more
pronounced effects of rare codon modification on expression.
Additionally, to conduct deeper analysis of codon-modified constructs, sorting was
conducted to purify transduced cultures using PR1/HLA-A2 tetramer. Cells were sorted into high
positive, intermediate positive, and negative populations. Once sorted, each population would
be able to be further analyzed to identify any possible effects of codon modification and rare
codon substitution in h8F4-CAR that could not be detected by flow cytometry. In addition to
sorting a negative population of cells to have negative sample to draw result comparisons from,
presence of non-surface expressed h8F4-CAR could be detected when conducting
immunoblotting or any future assays. Presence of non-surface expressed h8F4-CAR in surfacestained FACS negative populations could be attributed to inefficient or defective translation that
would not transport to the cell surface or prevent surface detection due to a defective product.
The principle of codon optimization and modification takes basis from a variety of
observations, evidences, and hypotheses that seek to explain inherent codon bias within the
genetic code. Evidence of the effects of altering codons in models and systems are not lacking.
Ward et al. demonstrated the promise of codon optimization in a potential gene therapy to treat
human factor VIII deficiency which is a cause of hemophilia A (32). Hoekema et al. demonstrated
the effects of introducing increasing numbers of rare codons via substitution and modification in
the PGK1 gene in Saccharomyces cerevisiae which led to decreased expression of the PGK1
protein (35). Scholten et al. demonstrated improvement in expression of transgenic T cell
receptors when codon optimizing  and  chains (33). Schutsky et al. demonstrated modest but
notable improvement in a transient CAR therapy platform when sequences were codon

52

optimized (34). Altogether, codon optimization and modification do indeed alter expression;
however, the mechanism by which this occurs has not been definitively determined. It is possible
that codon bias is a result of evolution to prefer codons that allow the most efficient translation
of products. Similarly, the effects of codon bias in genetic sequences and altering the codons
within them can result in defective/inefficient translation, ribosomal pausing, truncation of
product, protein misfolding, mRNA destabilization, and mRNA degradation (38).
While results seen from flow cytometry analysis of codon-modified h8F4-CAR constructs
do not directly show the effects of codon modification and substitution, immunoblotting of these
groups, both unsorted and sorted, clearly indicate alteration of h8F4-CAR. Figures #10A, 11, and
12 reveal novel and unique bands when probed using human anti-IgG antibodies to detect h8F4CAR. Each immunoblot reveals the expected bands at the correct molecular weight for h8F4-CAR;
however, novel and unique bands appear in the S30 and R27 constructs with some exceptions
for the S7(i) and RS30(i) constructs which also contain novel bands. It is possible that these bands
were isoforms of h8F4-CAR that have appeared as a result of codon modification and rare codon
substitution. These bands were clearly not seen in unmodified, wildtype h8F4-CAR nor mocktransduced cells or negative sorted populations. It is possible that rare codon introduction may
have caused premature truncation, ribosomal pausing, or defective translation. Figures #10B, 13,
and 14 do not show presence of any novel or unique bands which may be due to two factors.
First, translational issues caused by codon modification may result in premature truncation,
defective translation, or ribosomal pausing prior to reaching the predicted binding region for the
anti-CD28 and/or anti-CD3 antibodies. This would not allow detection of novel/unique bands.
Second, endogenous CD28 and CD3 bands that were present in Jurkat - cells may mask any
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bands that appear as a result of codon modification. Overall, codon modification does indeed
seem to cause alterations to h8F4-CAR that are more evident by immunoblotting.
Future directions for this study include studying the functionality of each of these codonmodified constructs via cytotoxicity and signaling assays in both HLA-A2+ and HLA-A2- human
peripheral blood mononuclear cells. Assessment of cytotoxic capabilities of each construct has
the potential to elucidate whether changes made at the codon and nucleic acid level have larger
downstream implications through transcription, translation, and eventually surface expression
and functionality. Since costimulatory and signaling domains of h8F4-CAR were codon-modified,
it is also imperative to assess whether any differences in signaling capabilities have resulted
compared to unmodified h8F4-CAR. Additionally, it is important to assess whether codon
modification results in any transcriptional or amplification differences since codons were
changed. This can be studied by designing primer/probe sets for the constructs and assay by
reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) experiments.
To continue studying novel bands in codon-modified constructs, mass spectrometry can
be employed to identify the contents of each band. This would not only allow determination of
what the contents of the bands are but also allow identification whether the final amino acid
within the sequence is a serine or arginine residue. If the final residue in the sequence is a serine
or arginine residue, this would indicate that translation was halted at a codon-modified residue
further providing evidence that codon modification indeed altered h8F4-CAR expression.
Furthermore, it is important to also study whether these effects could be reversed or modulated.
This could be possible through further study of tRNA pools for the cognate rare codons and
possible exogenous tRNA therapy to try and reverse alternate product production. Altogether,
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further studies, particularly functional studies, would elucidate and clarify the potential of using
the genetic code and inherent codon bias to reveal a unique modality to tune CAR-T cell therapies
and adoptive cellular therapies as a whole using the methods described in this work.

Figure #15. Future directions for h8F4-CAR codon modifications.

Figure #15. These experiments seek to continue studying the implications of using the natural
genetic code to beneficially improve and enhance biologic therapies such as h8F4-CAR as well as
other CAR and adoptive cell therapies. Additional experiments are critical to continue studying
the effect of codon modification to build on the findings and promise of this work.
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The aims of this project sought to develop and construct sequences encoding h8F4-CAR
with the introduction of rare codon modifications in order to test and determine the ability to
reveal an innovative method to modulate h8F4-CAR expression to avoid increased potential for
on-target, off-tumor toxicity. By strategically constructing and developing these h8F4-CAR
constructs bearing various permutations of rare codon modification, this created the
foundational groundwork to study the potential of rare codon modification in CAR therapies.
Additionally, testing and determining the effects of introducing rare codon modification allowed
a first-look at the effects on expression. As supported by flow cytometry and immunoblotting
data, the introduction of rare codons into h8F4-CAR indeed alters expression in the majority of
the rare codon-modified constructs. This is also supported by the subtle changes in surface
expression across the codon-modified constructs compared to wildtype, unmodified h8F4-CAR,
and is further supported to a greater extent by the appearance of novel and unique bands in
codon-modified constructs (S30, S7(i), RS30(i), and R27) by immunoblotting. Together, this
supports our hypothesis that introduction of rare synonymous codon modifications to h8F4-CAR
reduce and alter its expression as seen in 4 of the 6 rare codon-modified constructs. This further
lays the groundwork for studying the genetic code, codon bias, and rare codon modification as a
unique and innovative method to improve CAR therapies that target self-antigens and reduce the
potential for on-target, off-tumor toxicity.
In summary, the data presented in this work demonstrates the foundation upon which
therapies can harness the genetic code and codon bias to find unique methods to improve
therapies using its own genetic sequence. We demonstrate that 1) construction of rare codonmodified h8F4-CAR is possible; 2) codon-modified constructs can still express h8F4-CAR at the
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cell surface and at proper molecular weight; 3) h8F4-CAR is indeed altered in certain codonmodified constructs; and 4) this is evidenced by appearance of novel and unique bands seen in
immunoblots. We set steps forward to continue testing codon modification as a method to
improve and modulate h8F4-CAR therapy by 1) preparing to test and assay transcriptional and
transcriptional amplification differences by RT-qPCR; 2) conduct deeper analysis of novel and
unique bands found in immunoblots by mass spectrometry; 3) assess the functionality of each
codon-modified h8F4-CAR construct by conducting in vitro assays such as cytotoxicity and
signaling assays; and 4) investigate methods to reverse possible translational issues caused by
rare codon modification such as exogenous cognate tRNA therapy or supplementation for the
rare codons. Together these steps seek to continue validating results and pursue utilizing the
genetic code as a unique method to improve and enhance CAR and adoptive cellular therapies.
The data presented merits further investigation and study into codon modification of h8F4-CAR
as well as the mechanism of how codon modification alters h8F4-CAR expression and where this
alteration occurs.
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